

## ANNUAL GENERAL MEETING::VOLUNTARY

### Issuer & Securities

#### Issuer/ Manager

SINGAPORE PAINCARE HOLDINGS LIMITED

#### Security

SINGAPORE PAINCARE HOLDINGS LIMITED - SGXE51400773 - FRQ

### Announcement Details

#### Announcement Title

Annual General Meeting

#### Date & Time of Broadcast

15-Dec-2025 07:53:48

#### Status

New

#### Announcement Reference

SG251215MEETR9S1

#### Submitted By (Co./ Ind. Name)

Dr Lee Mun Kam Bernard

#### Designation

Executive Chairman and Chief Executive Officer

#### Financial Year End

30/06/2025

### Event Narrative

Narrative Type	Narrative Text
Additional Text	Please refer to the following: (i) Notice of Annual General Meeting (ii) Proxy Form (iii) AR Request Form
Additional Text	This announcement has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor").
Additional Text	It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange"), and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.
Additional Text	The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950

2188.

---

## Event Dates

---

### Meeting Date and Time

30/12/2025 14:00:00

---

### Response Deadline Date

27/12/2025 14:00:00

---

## Event Venue(s)

---

### Place

Venue(s)	Venue details
Meeting Venue	Seletar Country Club, 101 Seletar Club Road, Singapore 798273

---

## Attachments

---

[SPCH FY2025 Notice ADV.pdf](#)

---

[SPCH AGM Proxy Form.pdf](#)

---

[SPCH AR Request Form.pdf](#)

---

Total size =2247K MB

---

## NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the Annual General Meeting ("Meeting") of SINGAPORE PAINCARE HOLDINGS LIMITED (the "Company") will be held at Seletar Country Club, 101 Seletar Club Road, Singapore 798273 on Tuesday, 30 December 2025 at 2.00 p.m. to transact the following businesses:

### AS ORDINARY BUSINESS

- To receive and adopt the Directors' Statement and the Audited Financial Statements of the Company for the financial year ended 30 June 2025 together with the Independent Auditor's Report thereon. **(Resolution 1)**
- To approve the payment of Directors' Fees of up to S\$61,100 for the financial year ended 30 June 2025 (FY2024: up to S\$66,630). **(Resolution 2)**
- To re-elect the following Directors of the Company retiring pursuant to Regulation 97 of the Constitution of the Company:  
Dr. Lee Mun Kam, Bernard **(Resolution 3)**  
Dr. Lim Kah Meng **(Resolution 4)**  
(See Explanatory Note (i))
- To re-elect the following Director of the Company retiring pursuant to Regulation 103 of the Constitution of the Company:  
Dr. Kenneth Sheah Ban Joo **(Resolution 5)**  
(See Explanatory Note (ii))
- To re-appoint BDO LLP as the Independent Auditors of the Company and to authorise the Directors to fix their remuneration. **(Resolution 6)**
- To transact any other ordinary business which may properly be transacted at a Meeting.

### AS SPECIAL BUSINESS

To consider and if thought fit, to pass the following ordinary resolutions, with or without any modification:

- Authority to allot and issue shares**
  - Limited pursuant to Section 161 of the Companies Act 1967 of Singapore (the "Companies Act") and Rule 806 of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalyst ("Catalist Rules"), the Directors of the Company be authorised and empowered to:
    - allot and issue shares in the capital of the Company ("Shares") whether by way of rights, bonus or otherwise; and/or
    - make or grant offers, agreements or options (collectively, "Instruments") that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into Shares, at any time and upon such terms and conditions and for such purposes and to such persons as the Directors of the Company may in their absolute discretion deem fit; and
  - (notwithstanding that the authority conferred by this Resolution may have ceased to be in force) issue Shares in pursuance of any Instruments made or granted by the Directors of the Company while this Resolution was in force, provided that:
    - the aggregate number of Shares to be issued pursuant to this Resolution (including Shares to be issued in pursuance of the Instruments, made or granted pursuant to this Resolution) shall not exceed one hundred per centum (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of shares to be issued other than on a pro rata basis to existing shareholders of the Company shall not exceed fifty per centum (50%) of the total number of issued shares (excluding treasury shares and subsidiary holdings, if any) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below);
    - (subject to such calculation as may be prescribed by the SGX-ST) for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the percentage of the total number of issued Shares in the capital of the Company (excluding treasury shares and subsidiary holdings, if any) shall be calculated based on the total number of issued Shares in the capital of the Company (excluding treasury shares and subsidiary holdings, if any) at the time of the passing of this Resolution, after adjusting for:
      - new Shares arising from the conversion or exercise of the Instruments or any convertible securities outstanding at the time of passing of this Resolution;
      - (where applicable) new Shares arising from the exercise of share options or vesting of share awards outstanding or subsisting at the time of passing this Resolution, provided that such share options or share awards (as the case may be) were granted in compliance with the Catalist Rules; and
      - any subsequent bonus issue, consolidation or subdivision of Shares;
    - in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), all applicable legal requirements under the Companies Act and the Constitution of the Company; and
    - unless revoked or varied by the Company in a general meeting, such authority shall continue to be in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier. **(Resolution 7)**
- Authority to offer and grant options and to allot and issue shares pursuant to the SPCH Employee Share Option Scheme (the "Share Option Scheme")**

That pursuant to Section 161 of the Companies Act, authority be and is hereby given to the Directors of the Company to allot and issue from time to time such number of Shares as may be required to be issued pursuant to the exercise of options under the Share Option Scheme provided always that the aggregate number of new shares to be allotted and issued pursuant to the Share Option Scheme, SPCH Performance Share Plan, and all options granted under any other share option, share incentive, performance share or restricted share plan implemented by the Company shall not exceed fifteen per centum (15%) of the total number of issued shares in the capital of the Company (excluding treasury shares and subsidiary holdings, if any) on the day immediately preceding the date of offer of the employee share options.  
(See Explanatory Note (iv)) **(Resolution 8)**
- Authority to allot and issue shares under the SPCH Performance Share Plan**

That pursuant to Section 161 of the Companies Act, the Directors of the Company be authorised and empowered to offer and grant awards in accordance with the provisions of the SPCH Performance Share Plan and to allot and issue from time to time, such number of shares in the capital of the Company as may be required to be allotted and issued pursuant to the vesting of awards under the SPCH Performance Share Plan, provided always that the aggregate number of shares issued and issuable pursuant to vesting of awards granted under the SPCH Performance Share Plan, when added to (i) the number of shares issued and issuable in respect of all awards granted or awarded thereunder; and (ii) all shares issued and issuable in respect of all options granted or awards granted under the Share Option Scheme, and all options granted under any other share option, share incentive, performance share or restricted share plan implemented by the Company for the time being in force, shall not exceed fifteen per centum (15%) of the total number of issued shares in the capital of the Company (excluding treasury shares and subsidiary holdings, if any) on the day preceding the relevant date of the award.  
(See Explanatory Note (iv)) **(Resolution 9)**

By Order of the Board

Wong Yoen Har  
Company Secretary  
15 December 2025

### Explanatory Notes:

- Dr. Lee Mun Kam, Bernard will, upon re-election as Director of the Company, remain as Executive Chairman and Chief Executive Officer of the Company.  
Dr. Lim Kah Meng will, upon re-election as Director of the Company, remain as Non-Executive and Independent Director, Chairman of the Nominating Committee and Member of the Audit Committee and Remuneration Committee. The Board considers Dr. Lim to be independent for the purpose of Rule 704(7) of the Catalist Rules.
- Dr. Kenneth Sheah Ban Joo will, upon re-election as Director of the Company, remain as Non-Executive and Independent Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nominating Committee. The Board considers Dr. Sheah to be independent for the purpose of Rule 704(7) of the Catalist Rules.

### Key information on the retiring directors can be found in Board of Directors' section of the Annual Report.

- The Ordinary Resolution 7, if passed, will empower the Directors of the Company, effective until the conclusion of the next annual general meeting of the Company, or the date by which the next annual general meeting of the Company is required by law to be held or such authority is varied or revoked by the Company in a general meeting, whichever is the earlier, to issue Shares, make or grant Instruments convertible into Shares and to issue Shares pursuant to such Instruments, up to a number not exceeding, in total, 100% of the total number of issued shares in the capital of the Company (excluding treasury shares and subsidiary holdings, if any), of which up to 50% may be issued other than on a pro-rata basis to shareholders.  
For determining the aggregate number of shares that may be issued, the total number of issued Shares (excluding treasury shares and subsidiary holdings, if any) will be calculated based on the total number of issued Shares in the capital of the Company (excluding treasury shares and subsidiary holdings) at the time this Ordinary Resolution is passed after adjusting for new shares arising from the conversion or exercise of any convertible securities or share options or vesting of share awards which are outstanding or subsisting at the time when this Ordinary Resolution is passed and any subsequent bonus issue, consolidation or subdivision of Shares.
- The Ordinary Resolutions 8 and 9, if passed, will empower the Directors to grant options under the Share Option Scheme as well as to offer and award shares pursuant to the SPCH Performance Share Plan, provided that the aggregate number of shares to be issued shall not exceed fifteen per centum (15%) of the total number of issued shares in capital of the Company (excluding treasury shares and subsidiary holdings, if any) from time to time.

### IMPORTANT

#### Notes:

- Members of the Company are invited to **attend physically** at the Annual General Meeting (the "Meeting"). **There will be no option for members to participate virtually.**
- The Annual Report 2025, Notice of Annual General Meeting, Proxy Form and Request Form (to request hardcopy of the Annual Report 2025) will be made available to members by electronics means via publication on the Company's corporate website at the URL <https://sgpincare.com/investor-relations/> and will also be made available on the SGX website at the URL <https://www.sgx.com/securities/company-announcements>.
- Printed copies of the Notice of Annual General Meeting, Proxy Form and the Request Form (to request hardcopy of the Annual Report 2025) will be sent to members via post. Members who wish to obtain a printed copy of the Annual Report 2025 should complete the Request Form and return it by post to the Company's Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower Singapore 098632 or via email to [srs.requestform@boardroomlimited.com](mailto:srs.requestform@boardroomlimited.com) **no later than 5.00 p.m. on 22 December 2025.**

#### Submission of Instrument Appointing a Proxy ("Proxy Form") to Vote:

- A member who is not a relevant intermediary, is entitled to appoint one or two proxies to attend and vote at the Meeting. A member can appoint the Chairman of the Meeting as his/her/its proxy but this is not mandatory. The Chairman of the Meeting, as proxy, need not be a member of the Company.
- A member who is a relevant intermediary, is not entitled to appoint more than two proxies to attend and vote at the Meeting, but each proxy must be appointed to exercise the rights attached to a different Share or Shares held by such member.  
"Relevant intermediary" has the meaning ascribed to it in Section 181 of the Companies Act 1967.
- For Supplementary Retirement Scheme ("SRS") investors who hold their Shares through relevant intermediaries as defined in Section 181 of the Companies Act (including holders under depository agents) and who wish to exercise their votes should approach their respective relevant intermediaries (including their respective SRS Operators or depository agents) to submit their voting instructions in the Proxy Forms **at least seven (7) working days before the Meeting on 17 December 2025 at 5.00 p.m.**
- Members (whether individual or corporate) appointing a proxy or proxies must give specific instructions as to his manner of voting, or abstentions from voting, in the Proxy Form, failing which, the proxy/proxies will vote or abstain from voting at his/her discretion. A proxy need not be a member of the Company.
- The instrument appointing a proxy or proxies must be submitted to the Company in the following manner:
  - if submitted by post, be lodged with the Company's Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower Singapore 098632; or
  - if submitted electronically, be submitted via email to [srs.proxy@boardroomlimited.com](mailto:srs.proxy@boardroomlimited.com).in either case, **by 2.00 p.m. on 27 December 2025 (being at least 72 hours before the time for holding the Meeting).**
- A depositor shall not be regarded as a member of the Company entitled to attend and vote at the AGM unless his/her name appears on the Depository Register not less than seventy-two (72) hours before the time of the Meeting.
- The instrument appointing a proxy or proxies must be under the hand of the appointor or his/her attorney duly authorised in writing. Where the instrument appointing a proxy or proxies is executed by a corporation, it must be executed either under its common seal or under the hand of an officer or attorney duly authorised. Where the instrument appointing a proxy or proxies is executed by an attorney on behalf of the appointor, the letter or power of attorney or a duly certified copy thereof must be lodged with the instrument.
- The Company shall be entitled to reject the instrument appointing a proxy or proxies if it is incomplete, improperly completed, illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument appointing a proxy or proxies.

#### Submission of Questions in Advance:

- Shareholders may also submit questions related to resolutions to be tabled at the Meeting in the following manner:
  - if submitted by post, to the Company's Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower Singapore 098632; or
  - if submitted electronically, be submitted via email to [srs.teame@boardroomlimited.com](mailto:srs.teame@boardroomlimited.com).All questions for the Meeting must be submitted by 2.00 p.m. on 23 December 2025.
- A member who wishes to submit the questions in hard copy by mail is required to indicate the full name (for individuals)/company name (for corporates), NRIC/Passport No./Company Registration No., email address, contact number, shareholding type and number of shares held together with their submission, before submitting it by post to the address provided.
- The Board of Directors of the Company will endeavour to address all substantial and relevant questions received from Shareholders prior to the Meeting by publishing the responses to those questions on SGXNET at <https://www.sgx.com/securities/company-announcements> and the Company's website at <https://sgpincare.com/investor-relations/> at least forty-eight (48) hours prior to the closing date and time for the lodgement of the proxy forms. Where substantial relevant questions submitted by Shareholders are unable to be addressed prior to the Meeting, the Company will address them during the Meeting.

The Company shall only address relevant and substantial questions (as may be determined by the Company in its sole discretion) received. The Company will publish the minutes of the Meeting on SGXNET and the Company's website within one month from the date of the Meeting.

#### Personal data privacy:

By submitting a proxy form appointing a proxy or proxies to attend, speak and vote at the Meeting and/or any adjournment thereof, a member of the Company (i) consents to the collection, use and disclosure of the member's personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of the appointment of a proxy or proxies for the Meeting (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the Meeting (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "Purposes"), (ii) warrants that where the member discloses the personal data of the member's proxy(ies) and/or representative(s) to the Company (or its agents), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (iii) agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member's breach of warranty.

Photographic, sound and/or video recordings of the Meeting may be made by the Company for record keeping and to ensure the accuracy of the minutes prepared of the Meeting. Accordingly, the personal data of a member of the Company (such as his name, his presence at the Meeting and any questions he may raise or motions he propose/second) may be recorded by the Company for such purpose.

This Notice of Annual General Meeting has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this Notice of Annual General Meeting, including the correctness of any of the statements or opinions made, or reports contained in this Notice of Annual General Meeting.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.

**SINGAPORE PAINCARE HOLDINGS LIMITED**

(Company Registration No. 201843233N)  
(Incorporated in the Republic of Singapore)

**PROXY FORM  
ANNUAL GENERAL MEETING**

This proxy form has been made available on the SGXNET and the Company's website and may be accessed at the URLs: <https://sgpaincare.com/investor-relations/> and <https://www.sgx.com/securities/company-announcements>

**IMPORTANT:**

1. The Annual Report 2025, Notice of Annual General Meeting dated 15 December 2025, Proxy Form and Request Form have been made available on SGX website at the URL <https://www.sgx.com/securities/company-announcements> and the Company's website at URL <https://sgpaincare.com/investor-relations/>.
2. A relevant intermediary may appoint more than two proxies to attend the Annual General Meeting and vote (please see note 7 for the definition of "relevant intermediary").
3. The Chairman and proxy need not be a member of the Company.
4. By submitting this proxy form, the member accepts and agrees to the personal data privacy terms set out in the Notice of Annual General Meeting dated 15 December 2025.
5. Please read the notes overleaf which contain instructions on, *inter alia*, the appointment of the Chairman of the Meeting as a member's proxy and proxy to attend, speak and vote on his/her/its behalf at the Annual General Meeting.

I/We, \_\_\_\_\_ (Name) \_\_\_\_\_ (NRIC/Passport/Company Registration Numbers) of \_\_\_\_\_

being a member/members of Singapore Paincare Holdings Limited (the "Company"), hereby appoint:

Name	NRIC/Passport No.	Proportion of Shareholdings	
		No. of Shares	%
Address			

and/or (delete as appropriate)

Name	NRIC/Passport No.	Proportion of Shareholdings	
		No. of Shares	%
Address			

or failing the person, or either or both persons referred to above, the Chairman of the Meeting as my/our proxy/proxies to vote for me/us on my/our behalf at the Annual General Meeting (the "Meeting") of the Company to be held at Seletar Country Club, 101 Seletar Club Road, Singapore 798273 on Tuesday, 30 December 2025 at 2.00 p.m. and at any adjournment thereof. I/We direct my/our proxy/proxies to vote for or against the Resolutions proposed at the Meeting as indicated hereunder. If no specific direction as to voting is given or in the event of any other matter arising at the Meeting and at any adjournment thereof, the proxy/proxies will vote or abstain from voting at his/her discretion.

All resolutions put to the vote at the Meeting shall be conducted by poll.

No.	Resolutions relating to:	For	Against	Abstain
<b>ORDINARY BUSINESS</b>				
1	Adoption of the Directors' Statement and Audited Financial Statements of the Company for the financial year ended 30 June 2025 together with the Independent Auditor's Report			
2	Approval of the payment of Directors' Fees of up to S\$61,100 for the financial year ended 30 June 2025			
3	Re-election of Dr. Lee Mun Kam, Bernard as Director of the Company			
4	Re-election of Dr. Lim Kah Meng as Director of the Company			
5	Re-election of Dr. Kenneth Sheah Ban Joo as Director of the Company			
6	Reappointment of BDO LLP as the Independent Auditors of the Company and to authorise the Directors to fix their remuneration			
<b>SPECIAL BUSINESS</b>				
7	Authority to allot and issue ordinary shares			
8	Authority to issue shares under SPCH Employee Share Option Scheme			
9	Authority to issue shares under SPCH Performance Share Plan			

\* Voting will be conducted by poll. If you wish your proxy/proxies to vote all your shares "For" or "Against" the relevant resolution, please indicate with a "✓" in the "For" or "Against" box provided in respect of that resolution. Alternatively, please insert the relevant number of shares "For" or "Against" in the "For" or "Against" box provided in respect of that resolution. If you wish your proxy/proxies to abstain from voting on a resolution, please indicate with a "✓" in the "Abstain" box provided in respect of that resolution. Alternatively, please insert the relevant number of shares in the "Abstain" box provided in respect of that resolution.

Dated this \_\_\_\_\_ day of \_\_\_\_\_ 2025

Total number of shares in:	No. of shares
(a) CDP Register	
(b) Register of Members	

\_\_\_\_\_  
Signature of Shareholder(s)  
or, Common Seal of Corporate Shareholder

**IMPORTANT: PLEASE READ NOTES OVERLEAF**



#### Notes:

1. Please insert the total number of shares held by you. If you have Shares entered against your name in the Depository Register (as defined in Section 81SF of the Securities and Futures Act 2001 of Singapore), you should insert that number of shares. If you have shares registered in your name in the Register of Members, you should insert that number of shares. If you have shares entered against your name in the Depository Register and shares registered in your name in the Register of Members, you should insert the aggregate number of shares entered against your name in the Depository Register and registered in your name in the Register of Members. If no number is inserted, the instrument of proxy ("**Proxy Form**") shall be deemed to relate to all the shares held by you.
2. The instrument appointing a proxy or proxies must be under the hand of the appointor or of his/her attorney duly authorised in writing. Where the instrument appointing a proxy or proxies is executed by a corporation, it must be executed either under its common seal or under the hand of an officer or attorney duly authorised.
3. A member can appoint the Chairman of the Meeting as his/her/its proxy but this is not mandatory. The Chairman of the Meeting, as proxy, need not be a member of the Company.
4. Where a member (whether individual or corporate) appoints a proxy or proxies as his/her/its proxy, he/she/it must give specific instructions as to voting, or abstentions from voting, in respect of a resolution in the form of proxy, failing which, the proxy/proxies will vote or abstain from voting at his/her discretion.
5. A member who is a relevant intermediary entitled to attend the meeting and vote is entitled to appoint more than two proxies to attend and vote instead of the member, but each proxy must be appointed to exercise the rights attached to a different Share or Shares held by such member. Where such member appoints more than two proxies, the appointments shall be invalid unless the member specifies the number of Shares in relation to which each proxy has been appointed.
6. A proxy need not be a member of the Company.
7. Investors who hold their Shares through relevant intermediaries as defined in Section 181 of the Companies Act 1967 (including SRS investors) and who wish to exercise their votes by appointing a proxy or proxies should approach their respective relevant intermediaries to submit their voting instructions **by 5.00 p.m. on 17 December 2025, at least seven (7) working days before the Meeting**, in order to allow sufficient time for their respective relevant intermediaries to in turn submit a proxy form to appoint a proxy or proxies to vote on their behalf **by 2.00 p.m. on 27 December 2025**.
8. Completion and return of this instrument appointing a proxy or proxies shall not preclude a member from attending and voting at the Meeting. Any appointment of a proxy or proxies shall be deemed to be revoked if a member attends the meeting in person, and in such event, the Company reserves the right to refuse to admit any person or persons appointed under the instrument of proxy to the Meeting.
9. The instrument appointing a proxy or proxies must be submitted to the Company in the following manner:
  - (a) if submitted by post, be lodged with the Company's Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd., at 1 Harbourfront Avenue, #14-07 Keppel Bay Tower Singapore 098632; or
  - (b) if submitted electronically, be submitted via email to [srs.proxy@boardroomlimited.com](mailto:srs.proxy@boardroomlimited.com).in either case, **by 2.00 p.m. on 27 December 2025 (being at least 72 hours before the time for holding the Meeting)**.

A member who wishes to submit a Proxy Form must download, complete and sign the Proxy Form, before submitting it by post to the address provided above, or by scanning and sending it electronically to the email address provided above.

#### PERSONAL DATA PRIVACY:

By submitting a proxy form appointing a proxy or proxies, the member accepts and agrees to the personal data privacy terms set out in the Notice of Annual General Meeting dated 15 December 2025.

#### GENERAL:

The Company shall be entitled to reject the proxy form appointing a proxy or proxies if it is incomplete, improperly completed or illegible, or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the proxy form appointing a proxy or proxies. In addition, in the case of Shares entered in the Depository Register, the Company may reject any proxy form appointing a proxy or proxies lodged if the member, being the appointor, is not shown to have Shares entered against his name in the Depository Register as at 72 hours before the time appointed for holding the Meeting, as certified by The Central Depository (Pte) Limited to the Company.



## SINGAPORE PAINCARE HOLDINGS LIMITED

(Company registration no. 201843233N)  
(Incorporated in the Republic of Singapore)

15 December 2025

Dear Shareholder,

We are pleased to inform that the upcoming Annual General Meeting ("AGM") of Singapore Paincare Holdings Limited (the "Company") will be held on Tuesday, 30 December 2025 at 2.00 p.m. at Seletar Country Club, 101 Seletar Club Road, Singapore 798273. We hereby enclose printed copies of the Notice of AGM and Proxy Form for the Company's AGM.

In line with the Company's corporate social responsibility initiatives and sustainability efforts, we have discontinued the practice of mailing the Company's Annual Reports to shareholders. Instead, the Company's Annual Report for the financial year ended 30 June 2025 (the "Annual Report 2025") will be available for download or online viewing from the Company's corporate website and the website of the Singapore Exchange Securities Trading Limited ("SGX-ST") from the date of this letter. The Annual Report 2025 may be accessed at our website at <https://sgpaincare.com/investor-relations/> and on SGX-ST's website at <https://www.sgx.com/securities/company-announcements>. You will need an internet browser and PDF reader to view this document.

If you still wish to receive printed copies of the Annual Report 2025 for this year, please complete the request form below and return it to the Company's Share Registrar, Boardroom Corporate & Advisory Services Pte. Ltd. at 1 Harbourfront Avenue, #14-07, Keppel Bay Tower, Singapore 098632, no later than 5.00 p.m. on 22 December 2025 or email the completed request form to [srs.requestform@boardroomlimited.com](mailto:srs.requestform@boardroomlimited.com).

By completing, signing and returning the request form to us, you agree and acknowledge that the Company and its service providers may collect, use and disclose your personal data, as contained in your submitted request form or which is otherwise collected from you (or your authorised representative(s)), for the purpose of processing and effecting your request.

Yours faithfully  
For and on behalf of  
Singapore Paincare Holdings Limited

Wong Yoen Har  
Company Secretary

---

### Request Form

To: **Singapore Paincare Holdings Limited**

(Please tick accordingly. Incomplete, illegible or incorrectly completed forms will not be processed)

Please send me/us a printed copy of the Annual Report 2025.

The shares are held by me/us under or through:  CDP Securities Account  
 CPF/SRS Account  
 Physical Scrips

Name of Shareholder : \_\_\_\_\_

NRIC / Passport Number (last 4 digit) : \_\_\_\_\_

Company Registration Number : \_\_\_\_\_  
(for corporate shareholders only)

Mailing address : \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Signature & Date : \_\_\_\_\_

**Note: This request is valid for the Annual Report 2025 only**



*First fold*

---

**Request Form**

Please  
Affix  
Postage  
Stamp

**Singapore Paincare Holdings Limited**

c/o Boardroom Corporate & Advisory Services Pte. Ltd.

1 Harbourfront Avenue,  
#14-07, Keppel Bay Tower,  
Singapore 098632

*Second fold*

---

*Third fold*

---

← Apply glue here →